Flotufolastat F 18 Environmental Risk Assessment (ERA) report
Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
Not verified
Molecular formula
C63H99[18F]N12O25Si
Molecular weight
1470.631 g/mol
Drug class
18F-labelled prostate-specific membrane antigen (PSMA) PET radiotracerdiagnostic imaging agent
Mechanism of action
Binds prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells. PET imaging detects tracer distribution to localise PSMA-expressing prostate cancer lesions; it is a diagnostic radiopharmaceutical, not a therapeutic PSMA inhibitor.
Indications / reported uses
PET imaging of PSMA-positive lesions in men with prostate cancer to localise disease for initial staging or suspected recurrence, in conjunction with other diagnostic evaluations under the US PYLARIFY-like? specific product label; use only for the approved product indication and patient group
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Flotufolastat F 18 Environmental Risk Assessment (ERA) (the Flotufolastat F 18 ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.